SCHEMBL25874124

SCHEMBL25874124

Cc1nc(NCc2nccs2)c2nc(OCc3ccncc3)[nH]c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KHK P50053 2/20 0.37
TRPM5 Q9NZQ8 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
SYK P43405 1/20 0.33
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
KDM1A O60341 1/20 0.31
MAOB P27338 1/20 0.31
PIM1 P11309 1/20 0.31
DYRK1A Q13627 1/20 0.31
DYRK2 Q92630 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
MAOA P21397 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119860 0.88 HRH4 (0.36) KHKTRPM5HRH4SYKPDE4A
SCHEMBL25874026 0.84 KHK (0.36) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL25874033 0.83 KHK (0.35) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL25874137 0.81 KHK (0.35) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL25874012 0.80 KHK (0.34) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL20119595 0.80 CDK1 (0.38) KHKTRPM5HRH4SYKPDE4A
SCHEMBL20119859 0.77 NR1H3 (0.41) TRPM5PDE4APDE4BPDE4CPDE4D
SCHEMBL20119715 0.76 TRPM5 (0.36) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL20119772 0.74 HRH4 (0.37) KHKTRPM5HRH4KDM1AMAOB
SCHEMBL20119949 0.72 TLR7 (0.43) KHKTRPM5HRH4KDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KHK 2342/4885TRPM5 4390/4885HRH4 4263/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KHK 2342/4885TRPM5 4390/4885HRH4 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.